[Premium Alert Update] Open Quickly Volume Surged 14X (NYSE: PTN) Incredible Breakout Stock

Morning Update Regarding Big Mover (NYSE: PTN) PTN Volume Surge 14X Higher Than Daily Average Hi 10XProTrader Member, This message will be very brief, yet very important. Yesterday my premium alert (NYSE:PTN) turned out to have an incredible day. The stocks volume surged to 728,200 representing 14X greater the normal daily average volume of just 51,425 shares according to Yahoo Finance. Additionally (PTN) hit a staggering high of $2.70/share up 32% intra-day! I'm urging you and all of my 10X readers to keep (PTN) on the watchlist. This stock is trending very bullish. The Company has several bullish catalysts in the pipeline and is on the verge of potentially Disrupting a $566Bln Biopharmaceutical Space with their latest news, Palatin's Vyleesi® licensee Fosun Pharma reports first commercial sale in China and South Korean licensee Kwangdong Pharmaceuticals completes enrollment in phase 3 clinical study. Palatin has the potential to receive up to $92.5Mln in sales related milestones and high single-digit to low double-digit royalties on annual net sales in the licensed territory. Under the terms of the 2017 agreement with Fosun, Palatin granted Fosun an exclusive license to develop and commercialize bremelanotide (Vyleesi) in the territories of mainland China, Taiwan, Hong Kong and Macau. Palatin received an upfront payment of $5.0Mln and is due a $7.5Mln milestone based on regulatory approval by the Chinese National Medical Products Administration (NMPA). Palatin has the potential to receive up to $92.5Mln in sales related milestones and high single-digit to low double-digit royalties on annual net sales in the licensed territory. All development, regulatory, sales, marketing, and commercial activities and associated costs in the licensed territory are the sole responsibility of Fosun. Palatin has the potential to receive up to $37.5Mln in annual sales related milestones and mid-single-digit to low-double-digit royalties on net sales in the licensed territory. Under the terms of the 2017 agreement with Kwangdong, Palatin granted Kwangdong an exclusive license to develop and commercialize bremelanotide (Vyleesi) in the Republic of Korea for HSDD/FSD. Kwangdong is responsible for all regulatory and other development and clinical activities necessary for commercialization in the Republic of Korea. In exchange, Palatin received an upfront payment of $500,000 and is due a $3.0Mln milestone based on the first commercial sale in Korea. Palatin has the potential to receive up to $37.5Mln in annual sales related milestones and mid-single-digit to low-double-digit royalties on net sales in the licensed territory. News Link Here - snapshot below Palatin's Vyleesi® Licensee Fosun Pharma Reports First Commercial Sale in China and South Korean Licensee Kwangdong Pharmaceuticals Completes Enrollment in Phase 3 Clinical Study • First prescription dispensed in Chinese Hainan Province • 93% of patients enrolled completed the Phase 3 trial in preme∙nopausal pa∙tie∙nts with Hypoactive Se∙xu∙al Desire Disorder (HSDD) in South Korea CRANBURY, N.J., Aug. 8, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced that Fosun Pharma, the licensee of Vyleesi in China, reported its first sale in the Hainan Province of China. Palatin also announced that their South Korean licensee, Kwangdong Pharmaceuticals, completed enrollment in its Phase 3 clinical trial evaluating the efficacy and safety of Vyleesi in preme∙nopausal women with HSDD. Data from this trial is anticipated by year end with a potential regulatory submission in the first half of 2024. Vyleesi is the first and only as-needed treatment approved by the U.S. Food and Drug Administration (FDA) for preme∙nopausal women with acquired, generalized hypoactive se∙x∙ual desire disorder (HSDD). Vyleesi is marketed by Palatin in the U.S. and the Company recently announced its sixth consecutive quarter of double-digit growth in Vyleesi prescriptions dispensed. "We are excited by this significant achievement and advancement of Vyleesi in HSDD patients in China," stated Carl Spana, Ph.D., President, and Chief Executive Officer of Palatin. "This first commercial sale, coupled with the completed enrollment in the Phase 3 clinical trial in South Korea, strengthens our position in the Asian marketplace. After the Phase 3 data analysis is complete, we will be working closely with Kwangdong on the potential marketing application with the Korean regulatory authorities. We look forward to increasing patient use in China, to the potential approval in South Korea and expanding the availability and use of Vyleesi worldwide." Fosun's first sale of Vyleesi was dispensed through a medical institution in the Hainan Province, a free trade port in China, under which certain imported pharmaceutical products can be sold in Hainan without first receiving registration approval from the Chinese National Medical Products Administration (NMPA). The establishment of the Hainan Free Trade Zone (FTZ) is expected to further boost the medical tourism zone project and leverage market oppor∙tunities created by the growing demand for medical products and services. Kwangdong's Phase 3 study is a bridging, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of subcutaneously injected bremelanotide in preme∙nopausal women with hypoactive se∙x∙ual desire disorder (with or without decreased aro∙usal). The study enrolled 193 patients with 180 or 93% completing the study. Results of the study are currently expected later this year and the data will support a potential first-half 2024 submission to the Korean Ministry of Food & Drug Safety (MFDS) for potential marketing approval. Under the terms of the 2017 agreement with Fosun, Palatin granted Fosun an exclusive license to develop and commercialize bremelanotide (Vyleesi) in the territories of mainland China, Taiwan, Hong Kong and Macau. Palatin received an upfront payment of $5.0Mln and is due a $7.5Mln milestone based on regulatory approval by the Chinese National Medical Products Administration (NMPA). Palatin has the potential to receive up to $92.5Mln in sales related milestones and high single-digit to low double-digit royalties on annual net sales in the licensed territory. All development, regulatory, sales, marketing, and commercial activities and associated costs in the licensed territory are the sole responsibility of Fosun. Under the terms of the 2017 agreement with Kwangdong, Palatin granted Kwangdong an exclusive license to develop and commercialize bremelanotide (Vyleesi) in the Republic of Korea for HSDD/FSD. Kwangdong is responsible for all regulatory and other development and clinical activities necessary for commercialization in the Republic of Korea. In exchange, Palatin received an upfront payment of $500,000 and is due a $3.0Mln milestone based on the first commercial sale in Korea. Palatin has the potential to receive up to $37.5Mln in annual sales related milestones and mid-single-digit to low-double-digit royalties on net sales in the licensed territory. About Vyleesi® (bremelanotide injection) for Hypo∙active Se∙x∙ual Desire Disorder (HSDD) Vyleesi is the first and only as-needed treatment approved by the FDA for premen∙opausal women with acquired, generalized HSDD. Palatin is actively seeking Vyleesi collaborations for the United States and for territories outside the currently licensed territories of China and Korea. Vyleesi is licensed to Fosun Pharma in China and Kwangdong Pharmaceuticals in South Korea. ======================================================= Special Attention Needed: Your new Premium alert has a staggering 2,945.84% upside according to one Wall Street analyst. It has been a long time since I have discovered such an incredible biotech stock like (PTN) that has such an enormous upside potential according to analyst. The Company has several bullish catalysts in the pipeline and is on the verge of potentially Disrupting a $566Bln Biopharmaceutical Space with focuses on the research and development of targeted receptor therapeutics for a wide range of diseases and ailments. One of the key potential "catalysts" that could cause this biotech stock to surge in 2023 is their FDA approved drug, Vyleesi... which is the first FDA-approved melanocortin agent. Additionally, what draws me to (NYSE: PTN) right now is Multiple Analysts are Bullish and it has received a Buy rating from H.C. Wainwright analyst Joseph Pantginis. In his assessment, Pantginis emphasizes the undervaluation of the stock and maintains a price target of $70/share. Bullish Catalyst – H.C. Wainwright Reiterated a Buy rating on Palatin Technologies with a price target of $70.00. Initiating with Buy Rating and $70.00 PT According to H.C. Wainwright, Palatin Technologies (NYSE: PTN) has 2,945.84% upside potential, based on the analysts’ average price target. Bullish Catalyst – Ladenburg Thalmann Analyst Issued a Buy rating on Palatin Technologies (NYSE: PTN) with a price target of $50.00. Initiating with Buy Rating and $50.00 PT According to Ladenburg Thalmann, Palatin Technologies (NYSE: P TN) has 2,451.02% upside potential, based on the analysts’ average price target. Palatin Technologies (NYSE: PTN) is an overlooked under the radar biotech which has exceptional future potential in their FDA approved drug, Vyleesi. Vyleesi is their FDA-approved commercial product for pre∙men∙opausal women with HSDD. The goal of the Vyleesi program is to demonstrate commercial product value in the marketplace with an objective of licen∙sing the U.S. rights to a committed women’s health care company. Demonstrated Leader In The Discovery And Development of Melanocortin Agonist Treatments They have only just started tapping into the utility of melanocortin pathways in treating patients after establishing themselves with Vyleesi® (bremelanotide injection) for the treatment of (HSDD) in pre∙men∙opausal women, as the first FDA-approved melanocortin agent. They are focused on amplifying its commercial platform in North America, supporting commercialization partners globally, and subsequently relicensing to committed partners in the U.S. and worldwide. Their development arm builds on their proven success in bringing a melanocortin therapeutic from the lab to market by using their experience to propel their programs in ocular and autoimmune diseases through their clinical pipeline. Palatin Technologies is seeking lice∙nsing deals with additional markets for Vyleesi, which would unlock massive value for shareholders. In addition, their dry-eye disease dr∙ug is another upcoming bullish catalyst. Pioneering A New Treatment Paradigm For Ocular Diseases The need for innovative treatments for ocular indications remains unmet. Specifically, dry eye dis∙ease (DED) is a chronic, painful, and debilitating inflam∙matory eye condition that causes irritation, redness, discharge, and blurred vision. Over 20 mill∙ion people in the U.S. are estimated to be living with DED. Palatin is developing a truly novel class of dru∙gs that selectively bind to melanocortin receptors (MCR), with both MCR1 and pan-agonists, to directly activate natural pathways that resolve dise∙ase inflammation in the eye. Melanocortin agonists provide potential advantages over current options to better meet the needs of patients and clinicians by directly addressing harmful inflammation, resulting in rapid, global improvement of affected tissues. Their PL9643 ophthalmic solution (topical eye drops) is advancing into late-stage clin∙ical stu∙dies. Our Phase 2 stu∙dy demonstrated improvements in both the signs and symptoms of DED after just 2 weeks of trea∙tment, with no safety signals and excellent tolerability. Additional melanocortin receptor agonists are under inves∙tigation to resolve other inflammatory ocular dise∙ases, including non-infec∙tious uve∙itis, dia∙betic retin∙opathy, and dia∙betic ma∙cular ed∙ema. Palatin Technologies is a biopharmaceutical company specializing in developing peptide therapeutics for the treatment of diseases with significant unmet medical and commercial needs. Palatin's goal is to be a pioneer in a relatively new class of dru∙gs, the melanocortin agonists, which until recent years had no dru∙gs approved for human use. Their primary product and main success in this field is Vyleesi, the trade name for Bremelanotide, which is the first FDA-approved melanocortin agent for the treatment of HSDD in pre∙men∙opa∙usal women. It is quite a feat that the company has the world's first, and only, FDA approved ap∙hro∙disiac. Often referred to as “Fem∙ale∙ V,” Vyleesi is a very misunderstood dr∙ug and needs clarification against past competition, such as Ad∙dyi, which was developed by Sprout Pharmaceuticals. The main difference between these dru∙gs is the interaction with alco∙hol in the body Ad∙dyi was recommended to not be taken if accompanied by multiple drinks, whereas Vyleesi does not interact with alco∙hol at all. Another misunderstanding is that the dru∙g only works for women. Studies have shown that the dru∙g also has an effect in men. There is potential that Vyleesi could be pres∙cribed by a phys∙ician for off-label uses in men. Sprout Pharmaceuticals was acquired by Valeant in 2015 for $1bn, but was later re-acquired by CEO Cindy Eckert and shareholders in a truly unprecedented move. This acquisition, and subsequent reversal, shows the potential for a company like Palatin, whose stock remains undervalued and largely unappreciated by the inves∙tment community. The past acquisition of Sprout Pharmaceuticals shows that there is quite a bit of value waiting to be unlocked in this class of dru∙gs, to the tune of several hun∙dred mil∙lion, if not a bill∙ion do∙ll∙ars. Could PTN's FDA Approved Dru∙g, Vyleesi make it a "Prime Acquisition Target" for some of the Bigger Names in the Industry to Take Notice? There is a possibility that Palatin could become a potential prime acquisition target if it appeared on the radar of a larger pharmaceutical company. The question is, what entity is most likely to be this larger player, and what price would be fair for an acquisition? The few analysts who cover this company seem to be in agreement that there is significant upside for the shares, with price targets now ranging from $50.00 to as high as $70.00. Big Pharmas Signaling Accelerating Pace of M&A Big Pharma Companies have been striking on biotechs ripe for a takeover! Pharmaceutical and biotech companies spent $85bn on acquisitions in the first five months of the year, marking a dramatic recovery in dealmaking as they seek to replenish their dru∙g pipelines. The surge in M&A. compared to just $35.6bn in deals in the same period of 2022 and $49.1bn the year before, according to Stifel, an investment bank, is Being fueLled by large ca∙sh reserves amassed by Big Pharma during the I pand∙emic and inve∙stor concerns about future growth prospects. At the start of year, the world’s largest pharmaceutical companies held more than $1.4tn in dealmaking firepower, according to an analysis by EY. They also face the expiry of patents stretching to the end of the decade, which exposes $200bn of their top-selling branded dru∙gs to generic competition and will squeeze revenues. “Its a big turnaround and completely bucking the overall trend in the M&A market,” said Tim Opler, managing director at Stifel’s global healthcare group. “If we maintain the pace of the first five months and a week we would be on track to have a $215bn year.” In 2022 the total value of biopharma deals was $127bn while in 2021 it was $149bn. The Biotech Buying Bonanza Big Pharma has a problem, and a plan to solve it. The problem? A looming dr∙ug patent cliff that will unleash generic competition on some of the industry's biggest moneymakers. The solution? A breakneck M&A spree for biotech stocks, funded by a massive war chest built on drug companies' success in bringing new medical treatments to market. 'Blistering' M&A Pace As of April, pharma companies had announced $64bn in biotech mergers and acquisitions this year, with big names like Pfizer (PFE) and Merck (MRK) on the list of shoppers. That put biotech on a "blistering" M&A pace in 2023, according to inve∙stment bank Torreya, now a Stifel unit. Big Pharma Has Money To Spend On M&As Meanwhile, Big Pharma's M&A coffers continue to grow. Pharma companies have between $1.4tn and $1.5tn in ca∙sh, experts say. What Big Pharma Seeks In Biotech Companies Manmeet Soni, president of Reata Pharmaceuticals (RETA), estimates 15 to 20 pharmaceutical companies are looking to buy products. Reata is a biotech stock with a perfect Relative Strength Rating of 99, putting its 12-month price performance in the top 1% of all stocks, according to IBD Digital. He says Big Pharma's acquisition strategy has changed of late. Rather than seeking "platform" companies with a new technology to treat disease — such as CRISPR gene editing or messenger RNA companies — the buyouts in 2023 have been for small molecules. And Big Pharma is shopping for medicines that are ready for prime time now. Buyers are less interested in drugs they will have to spend time and money to further develop. The companies facing patent cliffs and Medicare negotiations need sales fodder sooner rather than later. Could Palatin Technologies (NYSE: PTN) become a "Potential Takeover Candidate" by one of the Large-cap Pharma and Biotech Companies? Typically, when these the large-cap pharma and biotech companies find something of real value, they get noticed. And when that happens the big players either join them or buy them, Hence – BUYOUT TARGET. If you haven't taken a look at this stock yet, this is your chance. Make sure you have PTN pulled up on your trading screen. 10X Your Wealth, Kevin Vander Publisher, 10XProTrader.com Investment Research You are receiving this e-mail as part of your subscription to 10XProTrader. Please do not reply to this e-mail as this address is not monitored. Our Customer Service team is available Monday - Friday between 9:00 AM and 5:00 PM ET. © 2023 10XProTrader.com. All Rights Reserved. Nothing in this email should be considered personalized financial advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular inves∙tment situation. N∙o communication by our employees to you should be deemed as personalized financial advice. We expressly forbid our writers from having a financial interest in any security recommended to our readers, prior or during our reporting on the company. © 2023 10XProTrader.com, All Rights Reserved. 10XProTrader is a financial publisher that does not offer any personal financial advice or advocate the purchase or sale of any security or inve∙stment for any specific individual. This communication is a paid a∙dvertisement. 10XProTrader.com and/or its subsidiaries and/or affiliates ("Company," "we," or "us") have been compensated $35,000 USD to disseminate this communication. We have never received stock in PTN, nor have we traded it. Please note that we do not trade any securities that we profile. We do not hold positions in stocks we profile. We do not except stock as a form of payment for our profiles. To view our disclosures and disc∙laimers in full, or for more information about this a∙dvertisement, visit [(. © 2022 10XProTrader. All rights reserved., 340 Royal Poinciana Way Suite 317, 33480, Palm Beach, United States You may [unsubscribe]( or [change your contact details]( at any time.